Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지

Dry-Heat Treatment Process for Enhancing Viral Safety of an Antihemophilic Factor VIII Concentrate Prepared from Human Plasma

  • Published : 2008.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

Viral safety is a prerequisite for manufacturing clinical antihemophilic factor VIII concentrates from human plasma. With particular regard to the hepatitis A virus (HAV), a terminal dry-heat treatment ($100^{\circ}C$ for 30 min) process, following lyophilization, was developed to improve the virus safety of a solvent/detergent-treated antihemophilic factor VIII concentrate. The loss of factor VIII activity during dry-heat treatment was of about 5%. No substantial changes were observed in the physical and biochemical characteristics of the dry-heat-treated factor VIII compared with those of the factor VIII before dry-heat treatment. The dry-heat-treated factor VIII was stable for up to 24 months at $4^{\circ}C$. The dry-heat treatment after lyophilization was an effective process for inactivating viruses. The HAV, murine encephalomyocarditis virus (EMCV), and human immunodeficiency virus (HIV) were completely inactivated to below detectable levels within 10 min of the dry-heat treatment. Bovine herpes virus (BHV) and bovine viral diarrhea virus (BVDV) were potentially sensitive to the treatment. However porcine parvovirus (PPV) was slightly resistant to the treatment. The log reduction factors achieved during lyophilization and dry-heat treatment were ${\geq}5.55$ for HAV, ${\geq}5.87$ for EMCV, ${\geq}5.15$ for HIV, 6.13 for BHV, 4.46 for BVDV, and 1.90 for PPV. These results indicate that dry-heat treatment improves the virus safety of factor VIII concentrates, without destroying the activity. Moreover, the treatment represents an effective measure for the inactivation of non-lipid-enveloped viruses, in particular HAV, which is resistant to solvent/detergent treatment.

Keywords

References

  1. Addiego, Jr. J. E., E. Gomperts, S. Liu, P. Bailey, S. G. Courter, M. L. Lee, G. G. Neslund, H. S. Kingdon, and M. J. Griffith. 1992. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography. Thromb. Haemost. 67: 19-27 https://doi.org/10.1055/s-0038-1648373
  2. Andrewes, C. 1989. Andrewes' Viruses of Vertebrates, pp. 120- 145. Balliere Tindal, London, U.K
  3. Berkman, S. A. 1988. Infectious complications of blood transfusion. Blood Rev. 2: 206-210 https://doi.org/10.1016/0268-960X(88)90026-4
  4. Boschetti, N., I. Niederhauser, C. Kempf, A. Stuhler, J. Lower, and J. Blumel. 2004. Different susceptibility of B19 virus and mice minute virus to low pH treatment. Transfusion 44: 1079-1086 https://doi.org/10.1111/j.1537-2995.2004.03420.x
  5. Burnouf, T. and M. Radosevich. 2000. Reducing the risk of infection from plasma products: Specific preventative strategies. Blood Rev. 14: 94-110. https://doi.org/10.1054/blre.2000.0129
  6. Carpenter, J. F., M. J. Pikal, B. S. Chang, and T. W. Randolph. 1997. Rational design of stable lyophilized protein formulations: Some practical advice. Pharm. Res. 14: 969-975 https://doi.org/10.1023/A:1012180707283
  7. Chudy, M., I. Budek, B. Keller-Stanislawski, K. A. McCaustland, S. Neidhold, B. H. Robertson, C. M. Nubling, R. Seitz, and J. Lower. 1999. A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J. Med. Virol. 57: 91-99 https://doi.org/10.1002/(SICI)1096-9071(199902)57:2<91::AID-JMV1>3.0.CO;2-L
  8. Dichtelmuller, H., D. Rudnick, B. Breuer, R. Kotitschke, M. Kloft, A. Darling, et al. 1996. Improvement of virus safety of a S/D treated factor VIII concentrate by additional dry heat treatment at $100^{\circ}C$. Biologicals 24: 125-130 https://doi.org/10.1006/biol.1996.0016
  9. Gummadi, S. N. 2003. What is the role of thermodynamics on protein stability? Biotechnol. Bioprocess Eng. 8: 9-18 https://doi.org/10.1007/BF02932892
  10. Hoyer, L. W. 1994. Hemophilia A. N. Engl. J. Med. 330: 38 https://doi.org/10.1056/NEJM199401063300108
  11. International Conference on Harmonisation. 1998. Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability. Federal Register 63: 51074-51084
  12. Jee, Y. M., U. Go, D. Cheon, Y. Kang, J. D. Yoon, S. W. Lee, et al. 2006. Detection of hepatitis A virus from clotting factors implicated as a source of HAV infection among haemophilia patients in Korea. Epidemiol. Infect. 134: 87-93 https://doi.org/10.1017/S0950268805004632
  13. Karber, J. 1931. Beitrag zur kollectiven Behandlung pharmakologische Reihenversuche. Arch. Exp. Path. Pharmak. 162: 480-483 https://doi.org/10.1007/BF01863914
  14. Kim, H., Y. Jee, H.-S. Mun, B.-C. Song, J.-H. Park, J.-W. Hyun, et al. 2007. Comparison of full genome sequences between two hepatitis B virus strains with or without preC mutation (A1896) from a single Korean hepatocellular carcinoma patient. J. Microbiol. Biotechnol. 17: 701-704
  15. Kim, I. S. 2003. Comparative inactivation of hepatitis A virus and murine encephalomyocarditis virus to various inactivation processes. Kor. J. Microbiol. 39: 242-247
  16. Kim, I. S., H. G. Eo, C. W. Park, C. E. Chang, and S. Lee. 2001. Removal and inactivation of human immunodeficiency virus (HIV-1) by cold ethanol fractionation and pasteurization during the manufacture of albumin and immunoglobulins from human plasma. Biotechnol. Bioprocess Eng. 6: 25-30 https://doi.org/10.1007/BF02942246
  17. Kim, I. S., Y. W. Choi, and S. R. Lee. 2004. Optimization and validation of a virus filtration process for efficient removal of viruses from urokinase solution prepared from human urine. J. Microbiol. Biotechnol. 14: 140-147
  18. Kim, I. S., Y. W. Choi, S. R. Lee, and H. M. Sung. 2004. Cold ethanol fractionation and heat inactivation of hepatitis A virus during manufacture of albumin from human plasma. Biotechnol. Bioprocess Eng. 9: 57-60
  19. Kim, I. S., Y. W. Choi, S. R. Lee, H. S. Woo, and S. Lee. 2001. Removal and inactivation of viruses during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. Biotechnol. 11: 497-503
  20. Kim, I. S., Y. W. Choi, S. R. Lee, M. S. Lee, K. H. Huh, and S. Lee. 2001. Removal and inactivation of hepatitis A virus during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. 39: 67-73
  21. Kim, I. S., Y. W. Choi, S. R. Lee, Y. Kang, K. M. Lee, D. H. Park, H. S. Woo, and S. Lee. 2002. Removal and inactivation of hepatitis A virus during manufacture of urokinase from human urine. Biotechnol. Bioprocess Eng. 7: 340-346 https://doi.org/10.1007/BF02933518
  22. Klein, H. G. 2005. Pathogen inactivation technology: Cleansing the blood supply. J. Intern. Med. 257: 224-237 https://doi.org/10.1111/j.1365-2796.2005.01451.x
  23. Laub, R. and P. Strengers. 2002. Parvovirus and blood products. Pathol. Biol. (Paris) 50: 339-348 https://doi.org/10.1016/S0369-8114(02)00303-6
  24. Lemon, S. M. 1994. The natural history of hepatitis A: The potential for transmission by transfusion of blood or blood products. Vox Sang. 67(Suppl 4): 19-23 https://doi.org/10.1111/j.1423-0410.1994.tb04539.x
  25. Morgenthaler, J. J. 2000. New development in plasma fractionation and virus inactivation. Vox Sang. 78(Suppl 2): 217-221 https://doi.org/10.1046/j.1423-0410.2000.7840217.x
  26. Mosley, J. W. and J. Rakela. 1999. Foundling viruses and transfusion medicine. Transfusion 39: 1041-1044 https://doi.org/10.1046/j.1537-2995.1999.39101041.x
  27. Murgatroyd, K. 1997. The freeze drying process, pp. 1-58. In P. Cameron (ed.), Good Pharmaceutical Freeze-Drying Practice. Interpharm Press, IL, U.S.A
  28. Powell J. S., M. Bush, J. Harrison, C. Abildgaard, E. Vosburgh, A. R. Thompson, and D. Hurst. 2000. Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80oC terminal dry heat treatment in patients with haemophilia A. Haemophilia 6: 140-149 https://doi.org/10.1046/j.1365-2516.2000.00407.x
  29. Roberts, P. L. and H. Hart. 2000. Comparison of the inactivation of canine and bovine parvovirus by freeze-drying and dry-heat treatment in two high purity factor VIII concentrates. Biologicals 28: 185-188 https://doi.org/10.1006/biol.2000.0256
  30. Robertson, B. H. and D. D. Erdman. 2000. Non-enveloped viruses transmitted by blood and blood products. Dev. Biol. Stand. 102: 29-35
  31. Robinson, S. M., H. Schwinn, and A. Smith. 1992. Clotting factors and hepatitis A. Lancet 340: 1465 https://doi.org/10.1016/0140-6736(92)92652-V
  32. Shin, J. S., Y. W. Choi, H. M. Sung, Y.-W. Ryu, and I. S. Kim. 2006. Enhanced virus safety of a solvent/detergent-treated antihemophilic factor IX concentrate by dry-heat treatment. Biotechnol. Bioprocess Eng. 11: 19-25 https://doi.org/10.1007/BF02931863
  33. Shin, K.-S., J. H. Lim, J.-H. Kim, H. Myung, and S.-W. Lee. 2006. Inhibition of the replication of hepatitis C virus replicon with nuclease-resistant RNA aptamers. J. Microbiol. Biotechnol. 16: 1634-1639
  34. Song, M.-S., Y. Joo, E. H. Lee, J.-Y. Shin, C.-J. Kim, K.-S. Shin, M. H. Sung, and Y. K. Choi. 2006. Genetic characterization of encephalomyocarditis virus isolated from aborted swine fetus in Korea. J. Microbiol. Biotechnol. 16: 1570-1576
  35. Tabor, E. 1999. The epidemiology of virus transmission by plasma derivatives: Clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 39: 1160-1168 https://doi.org/10.1046/j.1537-2995.1999.39111160.x